palbociclib-话题@MedSci - 梅斯（MedSci）

#palbociclib#

29篇内容 | 1857人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1372331, encodeId=0e7613e233184, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=BMC Cancer：质子泵抑制剂(PPIs)可降低转移性乳腺癌患者使用palbociclib和 ribociclib治疗的疗效, objectType=article, longId=727632, objectId=94b4e2763255, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94b4e2763255, replyNumber=0, likeNumber=90, createdTime=2022-05-25, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94b4e2763255, moduleTitle=BMC Cancer：质子泵抑制剂(PPIs)可降低转移性乳腺癌患者使用palbociclib和 ribociclib治疗的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=94b4e2763255)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372330, encodeId=ddf113e23302b, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=Clin Cancer Res：Palbociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的长期预后, objectType=article, longId=727037, objectId=b5dce27037f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5dce27037f6, replyNumber=0, likeNumber=120, createdTime=2022-05-17, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5dce27037f6, moduleTitle=Clin Cancer Res：Palbociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的长期预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b5dce27037f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372329, encodeId=220c13e232965, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=Eur J Cancer：Palbociclib或安慰剂联合氟维司群治疗HR+/HER2-晚期乳腺癌患者的疗效, objectType=article, longId=293782, objectId=8b44293e82df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b44293e82df, replyNumber=0, likeNumber=65, createdTime=2022-01-12, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b44293e82df, moduleTitle=Eur J Cancer：Palbociclib或安慰剂联合氟维司群治疗HR+/HER2-晚期乳腺癌患者的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8b44293e82df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372328, encodeId=a63f13e232873, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=Front Oncol： palbociclib联合来曲唑一线治疗HR+ /HER2- 转移性乳腺癌（MBC）原发性耐药的预测因素, objectType=article, longId=219744, objectId=b1bf219e44f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1bf219e44f1, replyNumber=0, likeNumber=80, createdTime=2021-11-05, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1bf219e44f1, moduleTitle=Front Oncol： palbociclib联合来曲唑一线治疗HR+ /HER2- 转移性乳腺癌（MBC）原发性耐药的预测因素, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b1bf219e44f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372327, encodeId=bd1713e232797, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤, objectType=article, longId=214664, objectId=c24a214664ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c24a214664ad, replyNumber=0, likeNumber=110, createdTime=2021-07-24, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c24a214664ad, moduleTitle=Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c24a214664ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372326, encodeId=96a013e2326d8, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=The Oncologist：Palbociclib联合内分泌治疗HR+/HER2-转移性乳腺癌的安全性分析：来自PALOMA系列5年随访综合分析更新, objectType=article, longId=211389, objectId=ad602113894a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad602113894a, replyNumber=0, likeNumber=76, createdTime=2021-05-17, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad602113894a, moduleTitle=The Oncologist：Palbociclib联合内分泌治疗HR+/HER2-转移性乳腺癌的安全性分析：来自PALOMA系列5年随访综合分析更新, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ad602113894a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372325, encodeId=a93f13e23259f, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=伦敦癌症研究所（ICR）：palbociclib有望治疗三阴性乳腺癌, objectType=article, longId=206378, objectId=97c82063e85a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97c82063e85a, replyNumber=0, likeNumber=96, createdTime=2021-01-30, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97c82063e85a, moduleTitle=伦敦癌症研究所（ICR）：palbociclib有望治疗三阴性乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=97c82063e85a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372324, encodeId=730c13e232456, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=Clin Cancer Res：PATRICIA试验 | Palbociclib联合曲妥珠单抗治疗HER2阳性晚期乳腺癌, objectType=article, longId=203556, objectId=4991203556ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4991203556ab, replyNumber=0, likeNumber=143, createdTime=2020-11-21, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4991203556ab, moduleTitle=Clin Cancer Res：PATRICIA试验 | Palbociclib联合曲妥珠单抗治疗HER2阳性晚期乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4991203556ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372323, encodeId=a36c13e232379, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=Breast Cancer Res Treat：Palbociclib加来曲唑作为雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的一线治疗效果, objectType=article, longId=195894, objectId=347c195894a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=347c195894a4, replyNumber=0, likeNumber=53, createdTime=2020-06-16, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=347c195894a4, moduleTitle=Breast Cancer Res Treat：Palbociclib加来曲唑作为雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的一线治疗效果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=347c195894a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372322, encodeId=ddf513e232298, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=男性乳腺癌：美国FDA批准IBRANCE（palbociclib）用于治疗HR+/HER2-的男性乳腺癌患者, objectType=article, longId=163717, objectId=ffde163e1796, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffde163e1796, replyNumber=0, likeNumber=107, createdTime=2019-04-07, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffde163e1796, moduleTitle=男性乳腺癌：美国FDA批准IBRANCE（palbociclib）用于治疗HR+/HER2-的男性乳腺癌患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ffde163e1796)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372321, encodeId=743f13e232171, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=NEJM：Palbociclib联合Fulvestrant治疗晚期乳腺癌, objectType=article, longId=153579, objectId=67ef1535e96c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67ef1535e96c, replyNumber=0, likeNumber=80, createdTime=2018-11-17, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67ef1535e96c, moduleTitle=NEJM：Palbociclib联合Fulvestrant治疗晚期乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=67ef1535e96c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372320, encodeId=b26913e232099, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=ANN ONCOL：Palbociclib治疗雌激素受体阳性HER2阴性转移性乳腺癌, objectType=article, longId=147428, objectId=fcbd14e42869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcbd14e42869, replyNumber=0, likeNumber=84, createdTime=2018-08-27, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcbd14e42869, moduleTitle=ANN ONCOL：Palbociclib治疗雌激素受体阳性HER2阴性转移性乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fcbd14e42869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372319, encodeId=85e513e231952, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=ANN ONCOL：Rb磷酸化调节与palbociclib抗增殖反应, objectType=article, longId=147418, objectId=967b14e41839, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=967b14e41839, replyNumber=0, likeNumber=81, createdTime=2018-08-27, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=967b14e41839, moduleTitle=ANN ONCOL：Rb磷酸化调节与palbociclib抗增殖反应, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=967b14e41839)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372318, encodeId=2ee313e2318c5, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=Slamon教授：Palbociclib研究历程及其在乳腺癌治疗中的作用, objectType=article, longId=145561, objectId=cdf014556159, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdf014556159, replyNumber=0, likeNumber=71, createdTime=2018-08-02, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdf014556159, moduleTitle=Slamon教授：Palbociclib研究历程及其在乳腺癌治疗中的作用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cdf014556159)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372317, encodeId=654613e231739, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=循环肿瘤DNA预测Palbociclib（帕博昔布）在乳腺癌患者中的有效性, objectType=article, longId=131451, objectId=84b5131451f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b5131451f8, replyNumber=0, likeNumber=76, createdTime=2018-03-06, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b5131451f8, moduleTitle=循环肿瘤DNA预测Palbociclib（帕博昔布）在乳腺癌患者中的有效性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=84b5131451f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372316, encodeId=85ce13e2316a8, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=The Oncologist：Palbociclib治疗CDKN2A突变难治性子宫平滑肌肉瘤的疗效良好, objectType=article, longId=92657, objectId=e1da9265eb5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1da9265eb5, replyNumber=0, likeNumber=59, createdTime=2017-03-22, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1da9265eb5, moduleTitle=The Oncologist：Palbociclib治疗CDKN2A突变难治性子宫平滑肌肉瘤的疗效良好, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e1da9265eb5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372315, encodeId=6f9313e2315ba, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=Clin Cancer Res：Palbociclib可阻止早期乳腺癌细胞增殖, objectType=article, longId=92064, objectId=537a9206468, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=537a9206468, replyNumber=0, likeNumber=91, createdTime=2017-03-18, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=537a9206468, moduleTitle=Clin Cancer Res：Palbociclib可阻止早期乳腺癌细胞增殖, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=537a9206468)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372314, encodeId=354113e23145e, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=NEJM：Palbociclib+来曲唑治疗可显著延长晚期乳腺癌患者的无进展生存期, objectType=article, longId=82539, objectId=ade982539bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ade982539bd, replyNumber=0, likeNumber=119, createdTime=2016-11-18, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ade982539bd, moduleTitle=NEJM：Palbociclib+来曲唑治疗可显著延长晚期乳腺癌患者的无进展生存期, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ade982539bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372313, encodeId=996913e23136f, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=JAMA Oncology：Palbociclib或许可以治疗多种癌症, objectType=article, longId=61483, objectId=4e96614834c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e96614834c, replyNumber=0, likeNumber=99, createdTime=2016-01-02, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e96614834c, moduleTitle=JAMA Oncology：Palbociclib或许可以治疗多种癌症, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4e96614834c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372312, encodeId=60ee13e2312f8, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, objectTitle=ESMO Asia 2015：帕布昔利布(palbociclib)+氟维司群治疗亚洲HR+/HER2-晚期乳腺癌女性疗效佳（PALOMA3试验亚洲结果）, objectType=article, longId=60863, objectId=28b16086327, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28b16086327, replyNumber=0, likeNumber=69, createdTime=2015-12-21, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28b16086327, moduleTitle=ESMO Asia 2015：帕布昔利布(palbociclib)+氟维司群治疗亚洲HR+/HER2-晚期乳腺癌女性疗效佳（PALOMA3试验亚洲结果）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=28b16086327)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

palbociclib

2020-05-29

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

BMC Cancer：质子泵抑制剂(PPIs)可降低转移性乳腺癌患者使用palbociclib和 ribociclib治疗的疗效

2022-05-25

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

Clin Cancer Res：Palbociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的长期预后

2022-05-17

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

Eur J Cancer：Palbociclib或安慰剂联合氟维司群治疗HR+/HER2-晚期乳腺癌患者的疗效

2022-01-12

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

Front Oncol： palbociclib联合来曲唑一线治疗HR+ /HER2- 转移性乳腺癌（MBC）原发性耐药的预测因素

2021-11-05

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤

2021-07-24

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

The Oncologist：Palbociclib联合内分泌治疗HR+/HER2-转移性乳腺癌的安全性分析：来自PALOMA系列5年随访综合分析更新

2021-05-17

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

伦敦癌症研究所（ICR）：palbociclib有望治疗三阴性乳腺癌

2021-01-30

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

Clin Cancer Res：PATRICIA试验 | Palbociclib联合曲妥珠单抗治疗HER2阳性晚期乳腺癌

2020-11-21

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

Breast Cancer Res Treat：Palbociclib加来曲唑作为雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的一线治疗效果

2020-06-16

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

男性乳腺癌：美国FDA批准IBRANCE（palbociclib）用于治疗HR+/HER2-的男性乳腺癌患者

2019-04-07

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

NEJM：Palbociclib联合Fulvestrant治疗晚期乳腺癌

2018-11-17

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

ANN ONCOL：Palbociclib治疗雌激素受体阳性HER2阴性转移性乳腺癌

2018-08-27

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

ANN ONCOL：Rb磷酸化调节与palbociclib抗增殖反应

2018-08-27

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

Slamon教授：Palbociclib研究历程及其在乳腺癌治疗中的作用

2018-08-02

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

循环肿瘤DNA预测Palbociclib（帕博昔布）在乳腺癌患者中的有效性

2018-03-06

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

The Oncologist：Palbociclib治疗CDKN2A突变难治性子宫平滑肌肉瘤的疗效良好

2017-03-22

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

Clin Cancer Res：Palbociclib可阻止早期乳腺癌细胞增殖

2017-03-18

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

NEJM：Palbociclib+来曲唑治疗可显著延长晚期乳腺癌患者的无进展生存期

2016-11-18

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

JAMA Oncology：Palbociclib或许可以治疗多种癌症

2016-01-02

ysjykql (审核中...)

前往app查看评论内容

#palbociclib#

ESMO Asia 2015：帕布昔利布(palbociclib)+氟维司群治疗亚洲HR+/HER2-晚期乳腺癌女性疗效佳（PALOMA3试验亚洲结果）

2015-12-21

科室
- - 订阅+
  - 更多科室
工具
服务